A new study led by researchers at the Montreal Neurological Institute and Hospital of McGill University and the MUHC, gets closer to identifying the mechanisms responsible for multiple sclerosis...
In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary...
The Montreal Neurological Institute and Hospital – The Neuro at McGill University and the MUHC has Canada’s oldest MS clinic but is always innovating - striving for progress and better treatments...
A new study led by researchers at the Montreal Neurological Institute and Hospital of McGill University and the MUHC, gets closer to identifying the mechanisms responsible for multiple sclerosis...
RSS